null

null

null

null

null

null

null

null

null

Minimal traditional debt; primarily equity-financed via dilutive stock offerings; a 20% rate rise has negligible direct interest cost impact but raises equity capital cost significantly.

High indirect sensitivity; reliant on equity markets for cash raises; rising rates compress biotech valuations and increase cost of future capital rounds materially.

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Single-source biologics manufacturing (likely US-based CMO); key chokepoints are FDA-regulated API sourcing and specialized bone graft matrix raw material suppliers.

Minimal international revenue; nearly 100% US-focused; sovereign currency devaluation exposure is effectively zero in current operational stage.

Operates almost exclusively in the United States; no material international revenue markets identified; currency devaluation risk is not applicable at current scale.

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on Norwood Financial/CMO partner for NELL-1 protein manufacturing; single biologics CMO likely represents non-substitutable operational input exceeding 30% of COGS.

Medical device/biologics developer; not cloud-infrastructure-dependent for core product delivery; cloud termination would disrupt admin/data systems but not primary product pipeline.

Pre-revenue clinical-stage biotech; secondary business model involves licensing IP (NELL-1 technology) from UCLA; royalty obligations exist regardless of cloud dependency.

Minimal API coupling risk; company is a clinical-stage biologics firm, not a SaaS platform; no significant third-party API integrations identified in core operations.

Low Howey Test risk; revenue model is product sales of bone graft biologics; not a token or investment contract structure; standard equity securities framework applies.

Very High

Low current exposure; clinical trial data governed by FDA/IRB frameworks; limited consumer PII collected; GDPR/CCPA exposure minimal given US-only clinical operations.

Low antitrust risk; small-cap pre-revenue firm with negligible market share in bone graft/spinal fusion market dominated by Medtronic, NovaBay, and Stryker.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Currently pre-revenue/negligible revenue; future model is 100% transactional (per-procedure product sales to hospitals/surgeons); no subscription or recurring contract revenue anticipated.

Direct product sales of DBM-NELL-1 bone graft substitute to hospitals and surgical centers; potential milestone and royalty payments from future licensing partnerships.

Pricing will mirror bone graft market ($500–$3,000 per unit); premium pricing possible if clinical superiority proven; stress scenario: commoditization pressure from allograft competitors.

Moderate-to-low near-term; must demonstrate clinical superiority over established grafts to command premium; reimbursement coding (CPT) will heavily constrain pricing flexibility.

Target gross margin 60–70% at commercial scale, typical for biologics; near-term margins negative due to pre-commercial manufacturing and fixed CMO costs.

No free-rider leakage problem applicable; single-use surgical product with no subscription element; surgeon/hospital adoption is the key retention variable post-launch.

Headcount-sublinear growth model; commercial-stage biologics can scale revenue through distributor networks without proportional internal headcount growth; current team is ~10 FTEs.

Marginal cost of growth is primarily manufacturing scale-up and distributor commissions; R&D headcount largely fixed; revenue scaling does not require linear headcount addition.

Not applicable; Bone Biologics does not operate a franchise network; distribution will be through independent surgical distributors with standard compliance agreements.

At 10x scale, CAC efficiency improves via distributor leverage; key metric is cost-per-surgeon-conversion; estimated CAC per account $5,000–$15,000 via medical rep/distributor model.

No meaningful network effects; biologics product adoption is driven by clinical evidence and surgeon habit, not user-base size; network effect durability is not applicable.

-27.8% Return on Assets (Negative equity)

Moderate recession resistance; elective spinal fusion procedures decline in recessions (~10–15% volume drop); trauma and urgent spinal cases remain relatively inelastic to economic cycles.

Orthopedic and spine surgeons at hospital systems and ambulatory surgical centers in the United States; high concentration risk with early adopter academic medical centers.

Hospital procurement committees and GPOs (Group Purchasing Organizations) controlling formulary access; gaining GPO contracts is critical to commercial scaling and revenue concentration risk.

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

0.0% CapEx / Revenue (Low-CapEx Asset-Light)

0001419554

BBLG